Please assess the completion status of the following clinical trial:

Trial Title: Effects of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients (Male \& female) ≥40 years of age~* Type 2 DM~* Best corrected visual acuity ≥ 20/200 (Snellen equivalent using Early Treatment Diabetic Retinopathy Study chart)~* central retinal thickness of ≥300 µm on optical coherence tomography~* nonproliferative diabetic retinopathy (NPDR) with diabetic macular edema~Exclusion Criteria:~* proliferative diabetic retinopathy~* Vitreous hemorrhage~* previous history of vitreoretinal surgery, post-cataract operation status (≤4 months before participation in this study)~* prior treatment with anti-VEGF drugs, intraocular corticosteroids, and/or retinal laser application~* Uncontrolled hypertension.~* Uncontrolled glaucoma.~* If both eyes met the study inclusion criteria, the more severely affected eye was selected

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lucentis (Type: EXPERIMENTAL): Patients were administered 0.5-mg IVR injections monthly for 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).